Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2022 call → NOWe need to answer YES or NO based on the criteria. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to check the transcript. The company is KeyCorp, a bank. Management discusses various things: interest rate positioning, deposits, loans, expenses, credit quality, etc. They mention investments in healthcare, renewable energy, affordable housing. They mention Laurel Road, GradFin acquisition. They talk about growing consumer households, senior bankers, Laurel Road members. They talk about loan growth from commercial and consumer. They mention that they are adding relationships with targeted clients. They talk about investment banking pipelines, M&A activity. They talk about the impact of market conditions. But the question is specifically about narrating what counterparties are themselves doing and scaling. That is, are they describing specific customers or partners who are expanding, ramping up, building out, and that the company's own volume is a consequence of those parties' trajectories? For example, if a company supplies components to a manufacturer that is building new plants, and the supplier's outlook is based on that manufacturer's expansion plans. In this transcript, management talks about their clients in general terms. They mention "targeted scale sectors" like healthcare, renewable energy, affordable housing. They mention the Inflation Reduction Act and Bipartisan Infrastructure Bill allocating over $300 billion for energy transition. They mention growing relationships with healthcare providers and expanding Laurel Road business. They mention GradFin consultations. But they do not specifically describe identifiable counterparties' own ramps, launches, rollouts, capacity additions, etc. They talk about their own investments and focus.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.